BOS
EVGN icon

Bingham Osborn & Scarborough’s Evogene EVGN Stock Holding History

Bingham Osborn & Scarborough’s Portfolio EVGN Stock Details EVGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2,500
Closed -$79K – 146
2018
Q1 		$79K Buy
+2,500
New +$93.1K 0.01% 146

Other funds holding EVGN

WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MCM
Moon Capital Management New York $166M AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bingham Osborn & Scarborough's EVGN Position: Q2 2018 in Review

Bingham Osborn & Scarborough sold out of Evogene (EVGN) in Q2 2018, closing a stake of 2,500 shares — an estimated $79K sold.

Bingham Osborn & Scarborough first reported a position in EVGN in Q1 2018 and held it in 1 quarter. The position peaked at $79K in Q1 2018. 24 funds tracked by Wall St. Rank hold EVGN as of Q2 2018.

  • Bingham Osborn & Scarborough reported no remaining Evogene position as of Q2 2018 after selling out during the quarter.
  • Bingham Osborn & Scarborough sold 2,500 Evogene shares in Q2 2018, an estimated $79K.
  • Bingham Osborn & Scarborough first reported a position in Evogene in Q1 2018 and held it in 1 quarter.
  • Bingham Osborn & Scarborough's Evogene position peaked at $79K in Q1 2018.
  • 24 funds tracked by Wall St. Rank held Evogene as of Q2 2018.

Based on Bingham Osborn & Scarborough's 13F filing for Q2 2018, filed 27 Jul 2018.